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Abstract Background: Activation of the sympathetic nervous system is an important
feature in hypertension and congestive heart failure. A strategy for directly
modulating sympathetic nerve function is to reduce the biosynthesis of nor-
epinephrine (noradrenaline) via inhibition of dopamine-b-hydroxylase (DbH).
Objective: To assess the safety, tolerability, and pharmacokinetics of etami-
castat (BIA 5-453), a new DbH inhibitor, following repeated dosing.
Methods: A double-blind, randomized, placebo-controlled study was con-
ducted in healthy young male volunteers. Participants received once-daily
doses of placebo or etamicastat 25, 50, 100, 200, 400, or 600mg, for 10 days.
Results: Etamicastat underwent N-acetylation to its metabolite BIA 5-961.
Etamicastat and BIA 5-961 maximum concentrations were achieved at 1–3
and 2–4 hours, respectively, after dosing. Elimination half-lives ranged from
18.1 to 25.7 hours for etamicastat and 6.7 to 22.5 hours for BIA 5-961. Both
etamicastat and BIA 5-961 followed linear pharmacokinetics. The extent of
systemic exposure to etamicastat and BIA 5-961 increased in an approx-
imately dose-proportional manner, and steady-state plasma concentrations
were attained up to 9 days of dosing. Etamicastat accumulated in plasma
following repeated administration. The mean observed accumulation ratio
was 1.3–1.9 for etamicastat and 1.3–1.6 for BIA 5-961. Approximately 40% of
the etamicastat dose was recovered in urine in the form of parent compound
and BIA 5-961. There was a high variability in pharmacokinetic parameters,
attributable to different N-acetyltransferase-2 (NAT2) phenotype. Urinary
excretion of norepinephrine decreased following repeated administration of
etamicastat. Etamicastat was generally well tolerated. There was no serious
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adverse event or clinically significant abnormality in clinical laboratory tests,
vital signs, or ECG parameters.
Conclusion: Etamicastat was well tolerated. Etamicastat undergoes N-acety-
lation, which is markedly influenced by NAT2 phenotype. NAT2 genotyping
could be a step toward personalized medicine for etamicastat.
Trial Registration: EudraCT No. 2007-004142-33
Background
Activation of the sympathetic nervous system
is a common finding in congestive heart failure
and hypertension.[1-6] Adrenoceptor antagonists
can be used to inhibit such sympathetic activa-
tion, but a proportion of patients do not tolerate
the immediate hemodynamic impact, particularly
in heart failure.[7] An alternative strategy is to in-
hibit dopamine-b-hydroxylase (DbH; EC 1.14.17.1),
a mono-oxygenase that catalyses the conversion
of dopamine into norepinephrine (noradrenaline)
in the catecholamine biosynthetic pathway.[8]
Gradual sympathetic modulation by DbH inhib-
itors as opposed to abrupt inhibition observed
with b-adrenoceptor blockers (b-blockers) could
decrease the hemodynamic negative impact.[9]
Furthermore, inhibition of DbH also increases
dopamine release,[10,11] which can improve renal
function by causing renal vasodilatation and in-
ducing diuresis and natriuresis.[9,12,13]
Several DbH inhibitors have been thus far re-
ported;[14-16] however, both first- and second-
generation DbH inhibitors were found to have
low potency, poor DbH selectivity, and relevant
toxic effects.[17] Nepicastat (RS-25560-197),[8] a
third-generation DbH inhibitor, was found to
have much greater potency and to be devoid of
some of the problems associated with first- and
second-generation inhibitors. However, nepica-
stat was found to cross the blood-brain barrier
and to cause potentially significant CNS-related
adverse events (AEs).[18] Therefore, there still re-
mains an unmet clinical need for a potent, safe,
and peripherally selective DbH inhibitor.
Etamicastat [BIA 5-453; (R)-5-(2-aminoethyl)-1-
(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-
thione hydrochloride] (figure 1) is intended to
act as a reversible inhibitor of peripheral DbH
with limited access to the brain.[17] Following oral
administration of etamicastat, a blood pressure-
lowering effect was observed in studies performed
with spontaneously hypertensive rats (SHR). Both
the systolic and diastolic blood pressure (but not
the heart rate) were decreased in SHR rats in a
dose-dependent manner, an effect not observed
in normotensive control rats.[19] Chronically ad-
ministered etamicastat in drinking water also
significantly reduced both blood pressure and
norepinephrine urinary excretion in SHR rats. In
parallel, the urinary excretion of dopamine in-
creased significantly but only in SHR rats.[20]
Etamicastat safety, tolerability, and pharm-
acokinetics were investigated in a previous entry-
into-man single-dose, double-blind, randomized,



















Fig. 1. Structural formulae of etamicastat (BIA 5-453) and its acetylated metabolite BIA 5-961.
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the dose range 2–1200mg.[21] Maximum plasma
concentrations (Cmax) occurred at 1–3 hours after
dosing. Eliminationwas bi-compartmental, charac-
terized by a first short early elimination half-life
(t½) followed by a longer t½ of 16–20 hours for
etamicastat doses ‡100mg. In a food interaction
study in healthy subjects, the absorption of eta-
micastat was delayed by the presence of food, but
no significant effect was observed in the extent of
systemic exposure to etamicastat, as assessed by
the area under the plasma concentration-time
curve (AUC).[22]
N-Acetyltransferase (NAT) is one of the major
hepatic phase II enzymes involved in drug me-
tabolism. Humans express two functional NAT
isoforms: NAT1 and NAT2.[23] Data from a pre-
vious single-dose study showed that N-acetylation
by NAT2 appeared to be the main metabolic
pathway of etamicastat.[21] Plasma exposure to
the N-acetylated metabolite (BIA 5-961), which
was shown to be inactive in in vitro and in vivo
preclinical experiments (e.g. following intraperi-
toneal administration in mice and rats [BIAL
unpublished observation]), increased in a dose
proportional manner.
A high interindividual variability of pharmaco-
kinetic parameters of etamicastat and BIA 5-961
was observed following single doses of etamica-
stat in healthy subjects.[21] Pharmacogenomic
data showed that such variability is mainly de-
pendent upon the NAT2 phenotype (rapid or
slow acetylating ability).[21] Etamicastat was well
tolerated at all the investigated dose levels. In the
present work, we describe the results of a study
aiming to evaluate the safety, tolerability, and
pharmacokinetics of multiple-dose regimens of
etamicastat in young healthy male volunteers.
Population and Methods
Study Design and Ethics Compliance
This was a phase I, double-blind, randomized,
placebo-controlled, multiple-dose study investigat-
ing etamicastat oral doses of 25, 50, 100, 200, 400,
and 600mg administered once-daily for 10 days
to sequential groups of young healthy male sub-
jects. The study was conducted according to the
principles of the Declaration of Helsinki and the
Good Clinical Practice (ICH) guidelines. An In-
dependent Ethics Committee (Comite´ de Protec-
tion des Personnes [CCP] Ouest VI, Brest, France)
reviewed and approved the study protocol and
the subject information. Written informed con-
sent was obtained for each subject prior to en-
rolment in the study. Subjects were required to
sign a specific pharmacogenetic informed consent
form to allow NAT1 and NAT2 genotyping and
phenotyping.
Participants
Healthy male volunteers aged 18–45 years
were eligible for this study. Health status was
confirmed by medical history, physical examina-
tion and vital signs, electrocardiogram (ECG),
and laboratory workup, including hematology,
plasma biochemistry, urinalysis, and hepatitis B,
hepatitis C, and HIV serology performed at
screening.
Volunteers were excluded from participation
if they (i) had any clinically relevant disorder;
(ii) smoked more than 10 cigarettes per day;
(iii) had a history of drug abuse or alcoholism
within 1 year prior to admission; (iv) had an ECG
corrected QT (QTc) interval reading at screening
or enrolment >450ms; (v) had positive serologic
results for HIV antibodies, hepatitis B surface anti-
gen, and/or hepatitis C virus antibodies; (vi) had
positive results of urine drug screen (amphetamines,
barbiturates, benzodiazepines, cannabinoids, co-
caine, methadone, opiates, 3,4-methylenedioxy-
methamphetamine [ecstasy]) at screening and
admission; (vii) had used any investigational
drug within 90 days or prescription drug within
30 days prior to admission; (viii) had consumed
any caffeine-containing products (e.g. coffee, tea,
chocolate, or soda) in excess of six cups per day
(or equivalent), grapefruit, grapefruit-containing
products, or alcoholic beverages within 72 hours
prior to admission; or (ix) had used any over-the-
counter drugs including herbal supplements (ex-
cept for the occasional use of acetaminophen
[paracetamol], acetylsalicylic acid [aspirin] and
vitamins within the recommended daily allowance)
within 7 days prior to admission. No concomitant
Etamicastat Multiple-Dose PK in Healthy Subjects 227
ª 2010 Nunes et al., publisher and licensee Adis Data Information BV. Drugs R D 2010; 10 (4)
medication was allowed during the study unless
required to treat an AE.
Interventions
Participants underwent health status screening
within 28 days before admission to the study.
Following confirmation of eligibility, within each
group of eight volunteers, two subjects were
randomized to receive placebo and the remaining
six subjects to receive etamicastat. Etamicastat
doses of 25, 50, 100, 200, 400, and 600mg were
investigated in ascending order and the decision
to proceed to the next higher dose was made on
the basis of tolerability assessments of the previous
dose level.Due to the occurrence of amaculopapular
rash of probable infectious origin in three of eight
subjects in group 4 (placebo/etamicastat 200mg),
this group was repeated to rule out drug hyper-
sensitivity before escalating to the next dose level.
Subjects were admitted to the research facility
from day -2 (2 days before the first dose of inves-
tigational product) until approximately 72 hours
after the last dosing. Subjects were then dis-
charged from the research facility and instructed
to return for a follow-up visit 4–7 days later. At
admission, medical history, physical examina-
tion, and laboratory safety tests were updated.
Supine and standing blood pressure and heart
rate measurements and computerized 12-lead
ECG recordings were obtained at frequent inter-
vals during admission. Clinical laboratory tests
were repeated on days 4 and 10, and 72 hours
after the last dose (discharge). At the follow-up
visit, the medical history was updated and clinical
laboratory safety tests performed.
Etamicastat was administered once daily, in
the morning (between 7:30am and 9:00am), for
10 days (days 1–10). Capsules of etamicastat or
placebo identical in appearance were used. The
doses of investigational product were administered
with 250mL of water following an overnight
fasting of at least 8 hours. Subjects remained
fasted for at least 4 hours post-dose on day 1 and
day 10, and for at least 2 hours post-dose on the
remaining treatment days.
A diet low in monoamines was adopted. The
following food was not permitted from 3 days
prior first dosing through 72 hours after last
dosing:
 drinks – chocolate, cocoa, beer, alcohol,
orange juice;
 fruits – banana, pineapple, orange, grapefruit,
grapes, strawberries;
 dry fruits/nuts – almonds, peanuts, pistachios,
prunes;
 vegetables – tomatoes, eggplants, broad beans;
 meat and fish – smoked fish, liver, brains; and
 cheese and vanilla-flavored desserts.
A normal sodium diet (NaCl 7 g/day) was
provided.
Safety Assessments
Safety assessments consisted of AE monitor-
ing, physical examinations, vital signs measure-
ments, digital 12-lead ECG recordings, and clinical
laboratory tests. During admission, blood press-
ure and heart rate measurements using a
Dinamap (GE Healthcare, Chalfont St. Giles,
UK) blood pressure monitor using the oscillo-
metric method and 12-lead digital ECG record-
ings were taken in the supine position, after
resting for at least 10 minutes, at the following
times: (i) day -1 (the day prior to first dosing) –
time 0 (24 hours before first dosing) and 1, 2, 3, 4,
6, 8, 10, 12, and 16 hours after; (ii) day 1 (day of
first dosing) – pre-dose and 1, 2, 3, 4, 6, 8, 10, 12,
and 16 hours post-dose; (iii) from day 2 to day 9 –
pre-dose and 2 hours post-dose; and (iv) day 10
(day of last dosing) – pre-dose and 1, 2, 3, 4, 6, 8,
10, 12, 16, 24, 48, and 72 hours post-dose. Digital
ECGs were performed in triplicate (with an in-
terval of 5 minutes, with a difference of at least
1 minute between each of the three recordings).
The investigator was responsible for provid-
ing the interpretation of all ECGs. The results
included heart rate, PR interval, QRS interval,
QT interval, and QTc interval, with comments
on normality or abnormality. Two corrections
of the QT interval were investigated: Fridericia’s
correction (QTcF) and Bazett’s correction (QTcB).
The primary method of correction was QTcF.
A manual reading of the digital ECGs was
conducted to assess prolongation of QT/QTc
intervals.
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All clinical AEs were monitored throughout
the entire study period. Their severity (intensity)
was categorized according a three-point scale
(mild, moderate, and severe), and the causality
(potential relationship to drug) was assessed by
the investigator before breaking the blinding.
Pharmacokinetic Assessments and
Bioanalytical Methods
Blood samples (3mL) for determination of
plasma concentrations of etamicastat and its
metabolites were taken, by direct venepuncture
or an intravenous catheter, into lithium-heparin
tubes at the following times on days 1 and 10:
pre-dose, then at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and
16 hours post-dose. Further blood samples were
taken at 24, 36, 48, and 72 hours post-last dose.
Pre-dose blood samples were also taken on days
2–9. After collection, blood samples were centri-
fuged at approximately 1500 g for 10 minutes at
4C. The resulting plasma was then separated
into four aliquots of 250 mL and stored at -80C
until required for analysis. Urine samples for
pharmacokinetic assessments were collected at
pre-dose and over the intervals 0–4, 4–8, 8–12,
and 12–24 hours post-dose on day 1, and at pre-
dose and over the intervals 0–4, 4–8, 8–12, 12–24,
24–36, 36–48, 48–60, and 60–72 hours after the
last dose (day 10). Four aliquots of 500 mL were
prepared and stored at -80C until required for
analysis.
For the preparation of calibration samples,
etamicastat and BIA 5-961 were dissolved in
methanol to a final concentration of 250 mg/mL
(method in plasma) or 1250mg/mL (method in
urine). For the preparation of quality control (QC)
samples, a second set of stock solutions was pre-
pared. For calibration and QC samples, working
solutions inmethanol were added to plasma using a
ratio of 2/98 (v/v). For the preparation of the inter-
nal standard (ISTD) solution, reference standard
(BIA 5-1058; molecular formula C21H21F2N3OS)
was dissolved in methanol to a concentration of
1000mg/mL. Further dilutions to a final concen-
tration of 555ng/mL were done using methanol.
Plasma samples were vortexed and centrifuged
for 20 minutes at approximately 3362 g after un-
assisted thawing at room temperature. The method
involved the addition of 300 mL of acetonitrile/
ethanol (50/50, v/v) containing 555ng/mL of ISTD
and 300 mL of acetonitrile to 100 mL of plasma.
After protein precipitation at room temperature,
samples were centrifuged for 20 minutes at ap-
proximately 2773 g and 8C. The supernatant
was transferred into a deep well plate. An aliquot
of 10 mL of the supernatant was injected onto the
liquid chromatography coupled to mass spectro-
metric detection (LC-MS/MS) system. The ana-
lysis was done by separation with an injection
volume of 10 mL (10 mL in a 10 mL sample pool) in
reversed phase chromatography (column tempera-
ture 50C) followed bymass detection spectrometry.
Urine samples were vortexed and centrifuged
for 20 minutes at approximately 3362 g after un-
assisted thawing at room temperature. To an
aliquot of 20 mL urine, 80 mL lithium-heparin
plasma was added and precipitated by 300 mL of
ISTD solution. After protein precipitation and
short mixing at room temperature, samples were
centrifuged for 20 minutes at approximately
2773 g and 8C. The supernatant (250 mL) was
transferred into an ultrafiltration filter plate and
centrifuged for about 2 hours at approximately
2773 g and 20C. An aliquot of 5mL of the su-
pernatant was injected onto the LC-MS/MS sys-
tem. The analysis was done by separation with an
injection volume of 5 mL (5 mL in a 10mL sample
pool) in reversed phase chromatography (column
temperature 50C) followed by mass detection
spectrometry.
Plasma and urine concentrations of etamica-
stat and its metabolite BIA 5-961 were de-
termined using validated methods consisting of
LC-MS/MS. The LC-MS/MS system consisted of
a Rheos 2200 pump (Flux Instruments, Basel,
Switzerland), a PAL autosampler (CTC Ana-
lytics AG, Zurich, Switzerland) and a TSQQuan-
tum triple-stage quadrupole mass spectrometer
(Thermo Fisher Scientific, San Jose, CA, USA).
Separation was achieved using a Luna C8 (2),
2.0 · 5.0mm, 5 mm analytical column (Phenom-
enex, Torrance, CA, USA), a C8, 2.0 · 5.0mm,
5 mm precolumn filter (Phenomenex, Torrance,
CA, USA), a Gecko 2000 column heater (CIL,
Courbevoise, France) at 50C and a mobile phase
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(0.5mL/min) consisting of water containing 1.0%
formic acid (phase A) and acetonitrile containing
1.0% formic acid (phase B). The MS detector was
operated in positive ion mode.
Calibration curves – over the nominal con-
centration ranges of 5–5000 ng/mL for plasma
assay or 25–25000 ng/mL for urine assay – and a
set of QC samples (triplicates over three concen-
tration levels) were analyzed with each batch of
study samples. The QC samples were used to
monitor the performance of the assay. In plasma,
the data for the QC samples showed that the
overall imprecision of the method, measured by
the coefficient of variation, was £6.0% for eta-
micastat and £6.9% for BIA 5-961. The overall
accuracy (as the proportion of the determined
value in relation to the true or nominal value)
ranged from 93.5% to 98.0% for etamicastat, and
93.5% to 98.0% for BIA 5-961. In urine, the
overall imprecision was £10.0% for etamicastat
and £7.8% for BIA 5-961, and the overall accu-
racy ranged from 99.5% to 99.7% for etamicastat
and 97.2% to 100.8% for BIA 5-961. The lower
limit of quantification of the assay (LLOQ) was
5 ng/mL in plasma and 25 ng/mL in urine. Eta-
micastat, BIA 5-961 and reference standard (BIA
5-1058) were supplied by BIAL (Laboratory of
Chemistry, S. Mamede do Coronado, Portugal).
Pharmacodynamic Assessments
Urine for the assessment of urinary levels of
norepinephrine, dopamine, epinephrine and ho-
movanillic acid was collected on day 1 at pre-dose
and 0–4, 4–8, 8–12, and 12–24 hours post-dose,
and on day 10 at pre-dose and 0–4, 4–8, 8–12,
12–24, 24–36, 36–48, 48–60, and 60–72 hours
post-dose. After collection, 3mL aliquots of acid-
ified urine were prepared and stored at -80C.
The determination of urine levels of catechol-
amines was carried out by high performance LC
with electrochemical detection using a validated
method. The LC electrochemical detection sys-
tem consisted of a pump (Gilson 302) and a
stainless steel 5-mm ODS2 column (Biophase;
Bioanalytical Systems, West Lafayette, IN, USA),
measuring 250mm in length and 4.6mm in dia-
meter; samples were injected by means of an
automatic sample injector (Triathlon-Spark Hol-
land, Emmen, the Netherlands). The mobile phase
was a degassed solution consisting of citric acid
(0.1mmol/L), sodium octylsulfate (0.5mmol/L), so-
diumacetate (0.1mol/L),Na2EDTA (0.17mmol/L),
dibutylamine (1mmol/L), and methanol (10%
v/v), adjusted to pH 3.5 with perchloric acid
(2mol/L), and pumped at a rate of 1.0mL/min.
The detection was carried out electrochemically
with a glassy carbon electrode, an Ag/AgCl ref-
erence electrode, and an amperometric detector
(Intro-Antec Leyden for norepinephrine, dopamine,
epinephrine, and Gilson 141 for homovanillic acid);
the detector cell was operated at 0.75 V. The lower
limits of detection of norepinephrine, dopamine,
epinephrine, and homovanillic acid were 22, 19, 37,
and 500ng/L, respectively.
Determination of Subjects NAT1 and NAT2
Genotypes
The NAT1 and NAT2 genes were genotyped
for all subjects participating in the current study.
Genomic DNA was extracted from total venous
blood. For NAT1, eight single nucleotide poly-
morphisms (SNPs) were analyzed (190 C >T, 445
G>A, 459G>A, 559C>T, 560G>A, 640 T>G,
1088T>A, and 1095C>A) and the corresponding
genotypes determined. Associated genotypes were
defined according to the literature.[17,24] Subjects
were classified NAT1 rapid (fast) acetylators if
they carried the NAT1*10 (except NAT1*10/*14)
or NAT1*11 alleles, normal acetylators if they
carried the NAT1*4 or NAT1*3 alleles or the
NAT1*10/*14 genotype, and poor (slow) acety-
lators if they carried the NAT1*14 (except
NAT1*10/*14) or NAT1*17 alleles. For NAT2,
four coding SNPs were analyzed (191 G >A, 341
T >C, 590 G >A, and 857 G >A) and the corre-
sponding genotypes determined. Associated geno-
types were defined according to the literature.[25,26]
The NAT2*4 allele encodes for a fully active
enzyme and is considered the wild type (rapid
acetylator) allele. Subjects were classified NAT2
rapid acetylators if they carried the NAT2*4/*4
allele or the NAT2*4/*5, NAT2*4/*6 or NAT2*4/*7
genotype, and poor acetylators if they carried
the NAT2*5/*5, NAT2*6/*6 or NAT2*7/*7 alleles,
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or the NAT2*5/*6, NAT2*5/*7 or NAT2*6/*7
genotype.
Analyses
For this exploratory study, no formal sample
size calculation was performed. Eight subjects per
treatment (six subjects assigned to active treat-
ment and two subjects assigned to placebo) are a
standard number of subjects per treatment group
in early clinical trials in healthy subjects and were
considered compatible with a reasonable clinical
interpretation and descriptive statistics.
AEs were tabulated and summarized accord-
ing to the Medical Dictionary for Regulatory
Activities (MedDRA). Blood pressure, heart rate,

































































Caucasian 13 (86.7) 6 (100) 5 (83.3) 4 (66.7) 6 (50) 5 (83.3) 6 (100)
other 2 (13.3) 0 1 (16.7) 2 (33.3) 6 (50) 1 (16.7) 0
BMI = body mass index; SD = standard deviation.
Table II. Number (%) of subjects reporting any treatment-emergent adverse event

















Flatulence 1 (6.7) 1 (16.7)
Nausea 1 (8.3) 1 (16.7)
Vomiting 1 (8.3)
Pyrexia 1 (8.3)
Ear infection 1 (8.3)
Nasopharyngitis 1 (16.7) 1 (16.7)
Rhinitis 1 (6.7) 1 (16.7) 2 (33.3)
Pain in extremity 1 (8.3)
Dizziness 1 (16.7)
Headache 1 (6.7) 3 (25.0) 1 (16.7)
Syncope, vasovagal 1 (8.3)
Pruritus 1 (8.3)
Rash papular 3 (25.0)
Urticaria 1 (16.7)
Totala 3 (20.0) 2 (33.3) 0 4 (66.7) 5 (41.7) 1 (16.7) 6 (100)
a Some subjects reported more than one adverse event.
MedDRA =Medical Dictionary for Regulatory Activities.
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vital signs, and clinical laboratory data were
summarized using descriptive statistics. For the
laboratory safety data, out-of-range values were
flagged in the data listings and a list of abnormal
values was presented. Any clinically significant
abnormality was considered as an AE.
The following parameters were calculated for
supine systolic (SBP) and diastolic (DBP) blood
pressure, ECG-measured heart rate and QTcF:
maximum observed effect (Emax), time to Emax
(tEmax) and area under the effect-time curve over
24 hours (AUCEC). The parameters were sum-
marized using descriptive statistics. Emax and
DAUCEC (difference in AUCEC in relation to
AUCEC on day -1) were compared at day 1 and
day 10 between dose groups by using a one-way
analysis of variance with dose group as the fixed
effect. If global treatment effect was significant, a
multiple-comparisons Dunnett’s test was per-
formed to compare each dose group versus pla-
cebo. Emax at day 10 was tested versus Emax at day
1 using a paired Student’s t-test in each dose group.
The following pharmacokinetic parameters
for etamicastat and its metabolites were derived
by non-compartmental analysis from the in-
dividual plasma concentration-time profiles: time
of occurrence of Cmax (tmax); AUC from time zero
to the last sampling time at which concentrations
were at or above the limit of quantification
(AUCt) and AUC over 24 hours (AUC24), both
calculated by the trapezoidal rule, and AUC from
time zero to infinity (AUC¥), calculated from
AUCt + (Clast/lz), where Clast is the last quantifi-
able concentration; the apparent terminal rate
constant (lz) and corresponding terminal t½ cal-
culated from ln 2/lz; observed accumulation ratio
(RO), calculated from AUC24 (day 10)/AUC24
(day 1); and theoretical accumulation ratio (RT),
calculated from 1/(1 - e-lzt), where t is the dos-
ing interval. The volume of distribution (V/F)
and the renal clearance of drug from plasma
(CLR), calculated from Ae/AUC¥, where Ae is
the cumulative amount of drug excreted in the
urine, were also derived. Nominal sampling times
were used for the pharmacokinetic analysis. Plasma
concentrations below the limit of quantification of
the assay were taken as zero for all calculations. All
calculations were made using raw data.
Summary statistics of all data were reported,
as appropriate, using the geometric mean, arith-
metic mean, standard deviation (SD), coefficient
of variation (CV%), standard error of the mean
(SEM), median, and range (minimum and max-
imum). A nonlinear power model was used to
assess dose proportionality of Cmax and AUC24.
The relationship is written as a power function:
parameter = adoseb, where a is a constant, b is
the proportionality constant, and parameter is
Cmax or AUC24. Linearization of this relationship
gives: log parameter = log a + log doseb. The
relationship is dose proportional when b = 1. The
exponent of the power function, with 95% con-
fidence intervals (95% CI), was fitted to the in-









































Fig. 2. Plasma concentration (mean –SEM) vs time profiles of
etamicastat following single (day 1 [a]) and repeated (day 10 [b])
oral once-daily administration of etamicastat in the dose range
25–600mg (etamicastat 200mg: n =12; other dose groups: n= 6 per
dose group).
232 Nunes et al.
ª 2010 Nunes et al., publisher and licensee Adis Data Information BV. Drugs R D 2010; 10 (4)
dividual Cmax and AUC24. For determination of
time to steady-state of plasma concentrations, a
pairwise comparison for pre-dose concentra-
tions between day 2 and day 10 was performed by
dose group using a paired Student’s t-test. Values
at each period and cumulated values of urinary
catecholamines were summarized using descrip-
tive statistics by dose group.
The pharmacokinetic parameters were calculated
with WinNonlin (version 5.0.1, Pharsight Corpora-
tion,Mountain View, CA, USA). Statistical calcula-
tions were performed with SAS Software (version
8.2, SAS Institute Inc., Cary, NC, USA). The a risk
p-values reported are two-sided and the statistical
significance nominal limit was set to 0.05.
Results
Study Population
Of 94 participants screened, 37 were deemed
ineligible because they met exclusion criteria or
failed to show up at the start of the study. A total
of 57 male volunteers, aged 18–45 (median = 30)
years were enrolled in the study. The demo-
graphic characteristics of the study population by
treatment group are summarized in table I. One
subject administered placebo withdrew his con-
sent and was replaced. No relevant differences in
demographic characteristics were found between
treatment groups.
Safety Results
During the course of the study, a total of
32 treatment-emergent AEs were reported by
21 subjects (table II). The most frequent treatment-
emergent AE was diarrhea. There were no serious
AEs. All AEs were mild to moderate in intensity.
An outbreak of maculopapular rash occurred in
three subjects administered etamicastat 200mg.
Subjects had elevated antistreptolysin O titers,
and antibiotics were prescribed. In the three
subjects, histamine, tryptase C3, C4, and C1q
were normal, there was no hypereosinophilia and
Table III. Pharmacokinetic parameters of etamicastat following the first dose (day 1) and the final dose (day 10) of repeated administration of
etamicastat to healthy subjectsa
Parameter Dose Etamicastat dose group
25mg (n= 6) 50mg (n= 6) 100mg (n= 6) 200mg (n= 12) 400mg (n= 6) 600mg (n =6)
Cmax (ng/mL) First 23 –7 56 –17 128 –40 251 –72 468 – 99 722 – 265
Last 32 –12 65 –28 153 –40 275 –87 596 – 154 866 – 280
tmax (h) First 1.5 (0.5–2.0) 1.0 (1.0–3.0) 1.5 (1.0–3.0) 1.5 (1.0–4.0) 3.0 (1.0–5.0) 2.0 (1.0–3.0)
Last 1.0 (0.5–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 2.0 (1.0–3.0) 2.0 (1.0–2.0) 2.0 (1.0–2.0)
AUCt (ngh/mL) First 147 –108 399 –157 862 –283 1746 –521 3095 – 1056 4804– 1829
Last 397 –394 1018– 719 2302 –867 4125 –1437 7466 – 2865 9126– 4195
AUC24 (ngh/mL) First 165 –99 405 –150 863 –284 1748 –522 3097 – 1057 4806– 1830
Last 307 –183 664 –328 1460 –4733 2662 –886 4957 – 1860 6484– 2848
AUC¥ (ngh/mL) Last 562 –491 1334– 776 2740 –1168 4601 –1597 8094 – 3145 9826– 4605
t½ (h) First 8.7 – 7.6 13.7 –3.2 13.0 –3.0 14.7 – 1.9 13.7 –2.1 13.0 –3.3
Last 18.1 – 11.6 25.6 – 6.2 25.7 –3.6 22.2 –2.9 20.3 –2.6 20.3 –1.6
RT Last 1.7 – 0.7 2.1 – 0.4 2.1 – 0.2 1.9 – 0.2 1.8 –0.1 1.8 –0.1
RO Last 1.9 – 0.3 1.6 –0.3 1.7 – 0.1 1.6 – 0.2 1.6 –0.1 1.3 –0.2
CLR (L/h) Last 15.2 – 5.5 11.9 –1.9 14.6 –2.1 16.0 – 3.1 13.2 –2.0 15.2 –1.7
V/F (L) Last 343 –148 440 –125 540 –119 517 –135 393 – 107 445 – 40
a Data are given as mean –SD (median and range for tmax).
AUC24 =area under the plasma concentration-time curve from time 0 to 24 hours;AUCt =area under the plasma concentration-time curve from
time zero to time t; AUC¥ =area under the plasma concentration-time curve from time zero to infinity; Cmax =maximum concentration;
CLR = renal clearance; RO =observed accumulation ratio; RT= theoretical accumulation ratio; t½=elimination half-life; tmax = time to maximum
concentration; V/F = volume of distribution.
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there was a moderate increase of C-reactive pro-
tein. Although an infection appeared to be a
plausible cause, drug hypersensitivity could not
be ruled out. Thus, a decision was made to repeat
the placebo/etamicastat 200mg group before es-
calating to the subsequent dose level (placebo/
etamicastat 400mg).
Clinical laboratory evaluations indicated no
clinically significant abnormality. There was no
statistically significant change in QTcF. There
was no evidence for prolongation of the QT in-
terval. All QTcF values remained below the limit
of 0.450 seconds. There were no apparent trends
in ECG parameters over time, and there were no
apparent differences between dose groups.
Pharmacokinetic Results
Due to the occurrence of rash, the tenth dose
was skipped in two subjects administered etami-
castat 200mg, and the pharmacokinetic profiling
planned for day 10 was performed after day 9
dosing. All other subjects of the pharmacokinetic
population completed the treatment period as
planned.
Mean etamicastat plasma concentration-time
profiles following the first and last doses of
etamicastat are displayed in figure 2, and the
corresponding pharmacokinetic parameters are
presented in table III. As expected, etamicastat
was shown to be metabolized to BIA 5-961.
Plasma concentration-time profiles of BIA 5-961
are displayed in figure 3, and the corresponding
mean pharmacokinetic parameters are presented
in table IV. Figure 4 displays the mean trough
(pre-dose) plasma concentrations of etamicastat
and BIA 5-961 during the treatment period.
Etamicastat Cmax was reached 1–3 hours post-
dose and declined thereafter, with an approx-
imate mean apparent t½ of 9–15 hours following
the first dose of etamicastat and 18–26 hours
following repeated administration. Cmax of BIA
5-961 was reached 2–4 hours post-dose and de-
clined thereafter, with a mean t½ of 4–8 hours
following the first dose of etamicastat and 7–23
hours following repeated administration. Sys-
temic exposure to etamicastat and BIA 5-961 in-
creased with increasing doses on both day 1 and
day 10 (table V and figure 5). The apparent dose-
proportional increase in systemic exposure was
confirmed by the statistical analysis using an ex-
ponential regression model. Also, the comparison
of etamicastat and BIA 5-961 pharmacokinetic
parameters after log-transformation and dose-
normalization showed that Cmax, AUCt and
AUC24 following the first dose of etamicastat,
and Cmax, AUCt, AUC24, and AUC¥ following
the last dose were not significantly different be-
tween dose groups.
The RO indicating the extent to which etami-
castat accumulated relative to the first dose
ranged from 1.3 to 1.9. This ratio was lower than
RT, which ranged from 1.7 to 2.1. This is in
a












































Fig. 3. Plasma concentration (mean –SEM) vs time profiles of BIA
5-961 following single (day 1 [a]) and repeated (day 10 [b]) oral once-
daily administration of etamicastat in the dose range 25–600mg
(etamicastat 200mg: n= 12; other dose groups: n= 6 per dose
group).
234 Nunes et al.
ª 2010 Nunes et al., publisher and licensee Adis Data Information BV. Drugs R D 2010; 10 (4)
accordance with the apparent t½ of 9–15 hours
following etamicastat first dose and 18–26 hours
following etamicastat last dose. The RO for BIA
5-961 was also relatively low, ranging from 1.3
to 1.6.
The one-way analysis of variance using trough
(pre-dose) etamicastat plasma concentrations from
day 2 to day 10 showed that steady state was
reached at day 9 (200mg), day 8 (400mg) and
before day 6 for the remaining dose groups. For
BIA 5-961, steady state was reached at day 9 (200
and 600mg), day 8 (25mg), and before day 6 for
the remaining groups.
The cumulative amounts of etamicastat and
BIA 5-961 recovered in urine are displayed in
figure 6. Urine drug recovery occurred predomi-
nantly over the first 12 hours after etamicastat
administration. The excretion rate of etamicastat
ranged from 0.3– 0.1mg/h (25mg) to 8.5– 3.2mg/h
(600mg) following the first dose and from
0.4 – 0.2mg/h (25mg) to 10.6 – 2.8mg/h (600mg)
following the last dose. For BIA 5-961, the ex-
cretion rate ranged from 0.7 – 0.6mg/h (25mg) to
10.4 – 6.9mg/h (600mg) and from 0.753 – 0.560
mg/h (25mg) to 15.2 – 9.8mg/h (600mg), respec-
tively. Renal clearance was relatively similar at
the different dose levels, ranging from 11.9 to
16.0 L/h for etamicastat and from 11.3 to 14.8 L/h
for BIA 5-961.
The interindividual variability in the pharm-
acokinetic parameters was high for both etami-
castat and BIA 5-961, with mean CV close to
100% in some parameters. This variability is due
to the different subjects’ NAT2 phenotype
(fast/slow acetylating ability), which affects the
rate of biotransformation of etamicastat into
BIA 5-961. Table VI presents the distribution of
the different subjects’ NAT1 and NAT2 pheno-
types within each etamicastat dose group. No
relevant effect of NAT1 phenotype on etamica-
stat pharmacokinetics was apparent. Etamicastat
pharmacokinetics was shown to be markedly af-
fected by the NAT2 status (figure 7). The extent
of systemic exposure to etamicastat in NAT2
slow acetylators was 1.5–6.7 times higher than in
NAT2 fast acetylators. BIA 5-961 exposure was
Table IV. Pharmacokinetic parameters of BIA 5-961 following the first dose (day 1) and the final dose (day 10) of repeated administration of
etamicastat to healthy subjectsa
Parameter Dose Etamicastat dose group
25mg (n= 6) 50mg (n =6) 100mg (n =6) 200mg (n= 12) 400mg (n= 6) 600mg (n =6)
Cmax (ng/mL) First 65 –55 105– 67 119– 47 209 –212 625 –516 1286– 865
Last 66 –45 114– 73 166– 103 264 –279 731 –545 1420– 989
tmax (h) First 2.5 (1.0–3.0) 3.0 (1.0–5.0) 2.5 (2.0–4.0) 2.0 (2.0–5.0) 3.5 (2.0–5.0) 3.5 (2.0–5.0)
Last 3.0 (2.0–4.0) 2.5 (2.0–4.0) 2.0 (2.0–4.0) 4.0 (2.0–5.0) 2.5 (2.0–3.0) 3.5 (2.0–4.0)
AUCt (ngh/mL) First 403 –352 685– 389 838– 328 1518 –1239 4111 –3311 8291 –5172
Last 548 –315 924– 461 1634– 768 2699 –2011 7017 –5313 12203 –7229
AUC24 (ngh/mL) First 427 –340 694– 377 838– 329 1519 –1240 4113 –3312 8293 –5173
Last 513 –327 820– 398 1286– 582 2070 –1707 5603 –4239 10297 – 6560
AUC¥ (ngh/mL) Last 615 –355 1069– 524 1853– 905 2926 –2032 7356 –5477 12516 – 7277
t½ (h) First 3.9 – 1.1 5.2 –1.6 6.4 – 0.8 7.8 –1.1 7.5 – 1.0 7.0 –1.6
Last 6.7 – 3.0 15.8 –7.1 19.5 –8.9 22.5 –4.4 18.3 – 2.3 17.0 – 2.5
RT Last 1.1 – 0.1 1.6 –0.4 1.8 –0.5 1.9 – 0.3 1.77 – 0.1 1.6 – 0.1
RO Last 1.6 – 0.3 1.3 –0.5 1.5 –0.2 1.3 – 0.2 1.4 – 0.2 1.3 – 0.1
CLR (L/h) Last 14.8 – 4.4 11.6 –1.1 12.2 –3.4 12.7 – 3.3 11.3 – 2.0 13.6 –1.8
a Data are given as mean –SD (median and range for tmax).
AUC24 =area under the plasma concentration-time curve from time 0 to 24 hours;AUCt =area under the plasma concentration-time curve from
time zero to time t; AUC¥ =area under the plasma concentration-time curve from time zero to infinity; Cmax =maximum concentration;
CLR = renal clearance; RO =observed accumulation ratio; RT= theoretical accumulation ratio; t½=elimination half-life; tmax = time to maximum
concentration.
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1.5–3.5 times higher in rapid NAT2 acetylators.
These results explain the high variability observ-
ed in the main etamicastat and BIA 5-961
pharmacokinetic parameters.
Pharmacodynamic Results
The cumulative amounts of norepinephrine
recovered in urine over a 24-hour interval post-
dose on day 1 (first dose) and day 10 (last dose)
are displayed in figure 8. No relevant change
from day 1 to day 10 was observed in subjects
administered placebo (29.6 – 12.4 mg on day 10 vs
33.1 – 10.5 mg on day 1). Following repeated eta-
micastat administration, urinary excretion of norepi-
nephrine decreased, which is consistent with the
claimed DbH inhibitory effect of etamicastat. In
relation to the day 1 value, urinary excretion of
norepinephrine at day 10 decreased by 24%, 18%,
36%, 34%, 32%, and 34% following repeated ad-
ministration of etamicastat 25, 50, 100, 200, 400,
and 600mg, respectively. No relevant changes were
found in the urinary excretion of homovanillic
acid, epinephrine and dopamine in the different
dose groups.
Due to the expected pharmacologic effect of
etamicastat, supine SBP,DBP, and ECG-measured
heart rate (HR)measurements were considered as
pharmacodynamic variables. Following the first
dose of placebo or etamicastat 25, 50, 100, 200,
400, and 600mg, no significant changes in SBP,
DBP, or HR were observed. Following repeated
dosing, SBP and HR did not significantly change
at any dose levels, but a significant decrease in
DBP occurred with etamicastat 100mg and 200mg
doses. In relation to day 1, DBP Emax and AUCEC
decreased by 5.6mmHg (p< 0.01) and 223mmHgh
(p < 0.05) following etamicastat 100mg and by
5.9mmHg (p < 0.05) and 193mmHgh (p < 0.05)











































Fig. 4. Trough (pre-dose) plasma concentrations (mean –SEM) of
(a) etamicastat and (b) BIA 5-961 during oral once-daily adminis-
tration of etamicastat in the dose range 25–600mg (etamicastat
200mg: n= 12; other dose groups: n =6 per dose group).
Table V. Proportionality of maximum concentration (Cmax) and area under the plasma concentration-time curve from time 0 to 24 hours








fold increase in Cmax fold increase in AUC24 fold increase in Cmax fold increase in AUC24
first dose last dose first dose last dose first dose last dose first dose last dose
25 (n= 6) 1 1 1 1 1 1 1 1 1
50 (n= 6) 2.0 2.4 2.0 2.5 2.2 1.6 1.7 1.6 1.6
100 (n =6) 2.0 2.3 2.4 2.1 2.2 1.1 2.5 1.2 1.6
200 (n =12) 2.0 2.0 1.8 2.0 1.8 1.7 1.6 1.8 1.6
400 (n =6) 2.0 2.9 2.2 1.8 1.9 3.0 2.9 2.7 2.7
600 (n =6) 1.5 1.5 1.5 1.6 1.3 2.1 1.9 2.0 1.8
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Discussion
This trial constituted the second study with
etamicastat, a new DbH inhibitor, in humans.
The objectives of the study were to evaluate the
safety, tolerability, and pharmacokinetics of eta-
micastat in healthy male adults following repeated
administration. The study followed a standard
design commonly used in studies with identical
purposes. Etamicastat administered orally at doses
up to 600mg once daily for 10 days appeared to
be well tolerated. All AEs were mild to moderate
in intensity. Most subjects (83%) in the 600mg
etamicastat group reported diarrhea as an AE.
Diarrhea has also been reported at high etamicastat
doses in preclinical studies. DbH gene variants that
cause low plasma DbH have also been associated
with an increased propensity to report diarrhea.[27]
The data show that a marked decrease of DbH
activity can predispose to the occurrence of diar-
rhea. A papular rash of plausible infectious origin
occurred in three subjects under treatment with
etamicastat 200mg. There were no serious AEs or
clinically significant abnormalities in clinical labo-
ratory tests, vital signs, or ECG parameters.
Consistent with the results from a previous study
in which etamicastat single doses of 2–1200mg
were administered to young healthy subjects,[21]
etamicastat was shown to be metabolized to its
N-acetylated metabolite BIA 5-961 following
single and repeated administration of 25–600mg
once-daily doses. Cmax of etamicastat and BIA
5-961 were achieved at 1–3 hours and 2–4 hours
after dosing, respectively. Thereafter, etamicastat
a




















































































Fig. 5. Maximum plasma concentrations (Cmax) and area under the concentration-time curve from time 0 to 24 hours (AUC24) values
(mean –SEM) of (a and b) etamicastat and (c and d) BIA 5-961 following single (day 1) and repeated (day 10) oral once-daily administration of
etamicastat in the dose range 25–600mg (etamicastat 200mg: n = 12; other dose groups: n= 6 per dose group).
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plasma concentrations declined with a mean ap-
parent t½ of 9–15 hours following the first dose
and 18–26 hours following the last dose. Esti-
mated t½ values for BIA 5-961 were slightly
shorter than those of the parent drug. Both eta-
micastat and BIA 5-961 followed approximate
linear pharmacokinetics over the dose range
studied. The extent of systemic exposure to eta-
micastat increased in an approximately dose-
proportional manner following single and repeated
administration. Etamicastat accumulated in plasma
following repeated administration. The mean RO
was 1.3–1.9 for etamicastat and 1.3–1.6 for BIA
5-961. The identical accumulation ratio of BIA
5-961 is consistent with the slightly shorter t½ of
BIA 5-961 compared with that of etamicastat.
Steady-state etamicastat and BIA 5-961 plasma
concentrations were reached up to 9 days of eta-
micastat repeated administration.






slow normal fast slow fast
25 (n= 6) 0 4 2 3 3
50 (n= 6) 0 2 4 3 3
100 (n =6) 0 4 2 3 3
200 (n =12) 0 6 6 7 5
400 (n =6) 1 4 1 1 5
600 (n =6) 1 1 4 4 2
a






























































































































Fig. 6. Mean cumulative urinary excretion of etamicastat following single (day 1 [a]) and repeated (day 10 [b]), and BIA 5-961 following single
(day 1 [c]) and repeated (day 10 [d]) oral once-daily administration of etamicastat in the dose range 25–600mg (etamicastat 200mg: n = 12;
other dose groups: n =6 per dose group).
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Approximately 45% of the etamicastat dose
was recovered in urine collected up to 24 hours
post-dose in the form of parent drug and N-
acetylated metabolite. These data are consistent
with those from a study aiming to characterize
the absorption, distribution, metabolism, and ex-
cretion of etamicastat and metabolites following
an oral dose of [14C]-labeled etamicastat (BIAL
unpublished observation). Eleven days after ad-
ministration, approximately 95% of the adminis-
tered radioactivity had been excreted, two-thirds
in urine and one-third in feces. Biotransformation
of etamicastat occurred mainly via N-acetylation,
forming BIA 5-961, the major metabolite. How-
ever, glucuronidation, oxidation, oxidative de-
amination, and de-sulfation were also involved.
Renal clearance of etamicastat from plasma
following repeated oral administration of etami-
castat was 11.9–16.0 L/h, which is higher than the
glomerular filtration rate (7.6 L/h).
N-Acetylation is the major metabolic pathway
for etamicastat. Humans express two functional
NAT isoforms, NAT1 and NAT2. NAT1 has
broad tissue distribution whereas NAT2 is more
restricted, with higher levels of expression in
the liver and red blood cells.[23] NAT exhibits dif-
ferent substrate specificities. Human NAT1 and
NAT2 loci are highly polymorphic, with more
than 25 alleles identified in each locus.[28,29] With-
in this polymorphic population, different pheno-
types have been identified for both forms, NAT1
and NAT2. As an important metabolizing en-
a





















































































Fig. 7. Meanmaximum plasma concentrations (Cmax) and area under the concentration-time curve from time zero to the last sampling time at
which concentrations were at or above the limit of quantification (AUCt) of (a and b) etamicastat and (c and d) BIA 5-961 in rapid or poor
N-acetyltransferase-2 acetylators following single (day 1) and repeated (day 10) oral once-daily administration of etamicastat in the dose range
25–600mg (etamicastat 200mg: n =12; other dose groups: n= 6 per dose group).
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zyme in humans, the polymorphism of human
NAT expression, especially NAT2, raises con-
cerns about drug-drug interactions during clin-
ical use. In in vitro studies (BIAL unpublished
observation), etamicastat N-acetylation in cyto-
solic fraction showed a good correlation with
sulfamethazine NAT activity, a selective sub-
strate to NAT2, but not with p-aminosalicylic
acid, a selective substrate to NAT1, suggesting
that etamicastat N-acetylation is predominantly
driven by NAT2. These data are consistent with
the results from the current study and those of a
previous single-dose study in healthy subjects,[21]
which showed no apparent major influence of
NAT1 phenotype on etamicastat pharmacokinetics.
However, the contribution of NAT1 to etamicastat
metabolism should not be completely excluded,
since NAT2 is expressed predominantly in liver
whereas NAT1 is expressed ubiquitously.[23]
As demonstrated in figure 7, the extent of
systemic exposure to etamicastat differed mark-
edly between NAT2 poor and rapid acetylators.
The extent of systemic exposure to etamicastat in
NAT2 poor acetylators was 1.5–6.7 times higher
than that observed in rapid acetylators and, in-
versely, NAT2 rapid acetylators showed a 1.5- to
3.5-fold increase in systemic exposure to the N-
acetylated metabolite, confirming the involvement
of NAT2 in the biotransformation of etamicastat
into BIA 5-961. The magnitude of the effect of
NAT2 phenotype on etamicastat pharmacokine-
tics is a strong argument for genotyping partic-
ipants in further clinical trials with etamicastat.
Effective clinical translation would establish eta-
micastat pharmacogenomics as a step toward
personalized medicine for etamicastat.
Similar to a previous single-dose study,[21]
the distribution of fast and slow NAT2 acetyla-
tors was not equal in all dose groups in the current
study, and differences in the proportion of NAT2
fast/slow acetylators complicated the interpreta-
tion of the results (i.e. the dose-proportionality
assessment) and were a cause of variability. To
facilitate the interpretation of the results, strat-
ification according to NAT2 phenotype could be
considered in future studies with etamicastat.
DbH catalyzes the conversion of dopamine
into norepinephrine. Consistently with the claimed
DbH inhibitory effect by etamicastat, urinary
excretion of norepinephrine decreased following
repeated administration of etamicastat. For doses
of etamicastat 100mg and above, the decrease in
norepinephrine urinary excretion was 32–36%. It
should be taken into account, however, that the
reported effect may be underestimated, since day
1 values do not correspond to a true baseline be-
cause they might have been influenced by the ef-
fect of the first dose of etamicastat. No relevant
change from day 1 to day 10 was found in the
other urinary catecholamines in the different dose
groups.
A statistically significant decrease was found
in supine DBP following repeated administration
of etamicastat 100mg and 200mg. Although
consistent with the claimed pharmacologic effect,
this effect, however, should be interpreted with
caution because no clear dose-response relation-
ship was observed and the number of subjects in
each dose group is small.
Conclusions
In conclusion, etamicastat was well tolerat-






































Fig. 8. Mean cumulative urinary excretion of norepinephrine (nor-
adrenaline) during a 24-hour period following the first (day 1) and last
(day 10) doses of a once-daily regimen of placebo and etamicastat in
the dose range 25–600mg (placebo: n =14; etamicastat 200mg:
n= 12; other dose groups: n =6 per dose group).
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N-acetylated metabolite BIA 5-961, following
single and multiple doses of etamicastat 25–600mg.
Etamicastat and its metabolite followed linear
pharmacokinetics, and steady-state plasma con-
centrations were attained up to 9 days of dosing.
Etamicastat pharmacokinetics are markedly af-
fected by the NAT2 phenotype, and NAT2 geno-
typing could be a step toward personalizedmedicine
for etamicastat. Consistently with the expected
pharmacologic effect, urinary excretion of nor-
epinephrine decreased following repeated admin-
istration of etamicastat.
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